{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T02:22:43Z","timestamp":1720318963000},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.parkreldis.2016.05.011","type":"journal-article","created":{"date-parts":[[2016,5,14]],"date-time":"2016-05-14T04:24:22Z","timestamp":1463199862000},"page":"123-124","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reply to letter: Exogenous melatonin for Parkinson\u2019s disease: \u2018Waking up\u2019 to the need for further trials"],"prefix":"10.1016","volume":"29","author":[{"given":"Tiago Martins","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Castro Caldas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2016.05.011_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.parkreldis.2016.03.002","article-title":"Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson\u2019s Disease: systematic review and meta-analysis","volume":"27","author":"Rodrigues","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2016.05.011_bib2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/mds.26509","article-title":"Circadian system \u2013 a novel diagnostic and therapeutic target in Parkinson\u2019s disease?","volume":"31","author":"Videnovic","year":"2016","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.05.011_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.sleep.2005.04.004","article-title":"Melatonin for sleep disturbances in Parkinson\u2019s disease","volume":"6","author":"Dowling","year":"2005","journal-title":"Sleep. Med."},{"key":"10.1016\/j.parkreldis.2016.05.011_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00415-006-0390-x","article-title":"Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson\u2019s disease","volume":"254","author":"Medeiros","year":"2007","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2016.05.011_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285611406166","article-title":"Therapeutic potential of melatonin and its analogs in Parkinson\u2019s disease: focus on sleep and neuroprotection","volume":"4","author":"Srinivasan","year":"2011","journal-title":"Adv. Neurol. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016301638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802016301638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T01:52:38Z","timestamp":1536717158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802016301638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":5,"alternative-id":["S1353802016301638"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.05.011","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to letter: Exogenous melatonin for Parkinson\u2019s disease: \u2018Waking up\u2019 to the need for further trials","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2016.05.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}